Patents Assigned to University of Copenhagen
  • Patent number: 11911418
    Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: February 27, 2024
    Assignees: Norges Miljo-Og Blovitenskapelige Universitet (NMBU), Sykehuset Ostfold HF, University of Copenhagen
    Inventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
  • Publication number: 20240052000
    Abstract: The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.
    Type: Application
    Filed: December 15, 2021
    Publication date: February 15, 2024
    Applicants: Novozymes A/S, University of Copenhagen
    Inventors: Thomas Krogh Kallehauge, Annaleigh Ohrt Fehler, Adrian Sven Geissler, Jan Gorodkin, Jeppe Vinther
  • Patent number: 11819552
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 21, 2023
    Assignees: Rigshospitalet, University of Copenhagen
    Inventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
  • Patent number: 11813327
    Abstract: The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: November 14, 2023
    Assignee: UNIVERSITY OF COPENHAGEN
    Inventors: Peter Johannes Holst, Cyrielle Elyette Fougeroux
  • Patent number: 11793752
    Abstract: An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90% by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 24, 2023
    Assignee: University of Copenhagen
    Inventors: Daniel Bar-Shalom, Jette Jacobsen, Kasper Dalby, Anne Marie Lynge Pedersen, Peter Vilmann
  • Publication number: 20230277600
    Abstract: The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
    Type: Application
    Filed: October 19, 2022
    Publication date: September 7, 2023
    Applicants: University of Rochester, University of Copenhagen
    Inventors: Steven A. Goldman, Ricardo da Costa Barbedo Vieira
  • Publication number: 20230270140
    Abstract: A betalain pigment composition from red beet plants including pre-harvest foliar spraying of an ethylene-generating compound and the use of the obtained betalain pigment composition for coloring of an edible product
    Type: Application
    Filed: May 10, 2023
    Publication date: August 31, 2023
    Applicants: CHR. HANSEN NATURAL COLORS A/S, UNIVERSITY OF COPENHAGEN
    Inventors: Gregorio Barba ESPIN, Henrik Vlk LUETKEN, Bjarne JOERNSGAARD, Renate Petra Brigitte MUELLER, Tsaneta DZHANFEZOVA, Stephan GLIED, Bjoern MADSEN
  • Patent number: 11725037
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: August 15, 2023
    Assignee: University of Copenhagen
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • Publication number: 20230241118
    Abstract: The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 3, 2023
    Applicants: University of Rochester, University of Copenhagen
    Inventors: Steven A. Goldman, Ricardo da Costa Barbedo Vieira
  • Patent number: 11708569
    Abstract: The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 25, 2023
    Assignees: University of Copenhagen, GLYCODISPLAY APS
    Inventors: Claus Kristensen, Weihua Tian, Henrik Clausen, Zhang Yang, Sergey Vakhrushev
  • Publication number: 20230211307
    Abstract: The present disclosure provides methods, devices, systems and kits for producing polymeric microbeads, including lanthanide-encoded microbeads. Among others, the present disclosure provides methods, systems and kits for producing functionalized microbeads that include on their surfaces amphipathic moieties with free reactive groups that remain free and can be used for covalently coupling molecules or moieties of inters to the microbeads.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 6, 2023
    Applicants: Chan Zuckerberg Biohub, Inc., The Board of Trustees of the Leland Stanford Junior University, University of Copenhagen
    Inventors: Yinnian Feng, Adam K. White, Jamin B. Hein, Polly M. Fordyce
  • Patent number: 11690389
    Abstract: A method for obtaining a betalain pigment composition from red beet plants comprising pre-harvest foliar spraying of an ethylene-generating compound and the use of the obtained betalain pigment composition for coloring of an edible product.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: July 4, 2023
    Assignees: UNIVERSITY OF COPENHAGEN, OTERRA A/S
    Inventors: Gregorio Barba Espin, Henrik Vik Luetken, Bjarne Joernsgaard, Renate Petra Brigitte Mueller, Tsaneta Dzhanfezova, Stephan Glied, Bjoern Madsen
  • Patent number: 11680250
    Abstract: The present disclosure relates to a light-driven system which is able to chemically modify an organic substrate with high efficiency and in a cost-effective manner. Also provided are methods for chemically modifying an organic substrate using the present systems and methods for manufacturing such systems.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 20, 2023
    Assignee: University of Copenhagen
    Inventors: Claus Felby, David Cannella, Klaus Benedikt Möllers
  • Patent number: 11613736
    Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: March 28, 2023
    Assignee: University of Copenhagen
    Inventors: Jacqueline Ameri, Henrik Semb
  • Patent number: 11572399
    Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIPS-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 7, 2023
    Assignee: UNIVERSITY OF COPENHAGEN
    Inventors: Mette Marie Rosenkilde, Jens Juul Holst, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Maria Buur Nordskov Gabe
  • Patent number: 11554261
    Abstract: The present disclosure relates to a system for generating a predefined electrical signal in an MR scanner for use in electrical stimulation of a subject during MRI or functional MRI of said subject, wherein said MR scanner is located inside a shielded MRI room. The system comprises a control unit to be located outside the MRI room for generating an electrical signal and an electrical to optical converter to be located outside the MRI room for converting said electrical signal to a corresponding optical signal. An optical transmitting element, such as an optical fiber, is used for transmitting the optical signal into the MRI room, and an optical to electrical converter is used for converting the optical signal to said predefined electrical signal for electrical stimulation of the subject during magnetic resonance imaging. The optical to electrical converter is configured for being located inside the MRI room and for operation during magnetic resonance imaging.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: January 17, 2023
    Assignees: Roskilde/Køge Hospital, Rigshospitalet, University Of Copenhagen
    Inventors: Anders Ohlhues Baandrup, Louise Møller Jørgensen, Carsten Thomsen
  • Patent number: 11556045
    Abstract: A device for generating individual photons with energy E includes quantum emitters, having at least one determined transition with the energy E from an energy level N* to a lower energy level N1. The emitters are near a propagation path running from first to second regions. The device also includes at least one light source to output light, for propagation along the path. The light has the energy E for resonant excitation of the energy level N*. The emitters are arranged so that optionally exactly Z emitters are illuminated, forming an optical thickness ?>0 for the light along the path. The number Z lies in a range of Z0±10% and Z0 is a number at which a maximum destructive interference in the second region occurs between a two-photon component of the light scattered on the ZO emitters and a two-photon component of the non-scattered light.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: January 17, 2023
    Assignees: Humboldt-Universitaet zu Berlin, University of Copenhagen
    Inventors: Philipp Schneeweiss, Juergen Volz, Arno Rauschenbeutel, Sahand Mahmoodian, Anders Søndberg Sørensen
  • Publication number: 20230004850
    Abstract: Provided is a quantum computing device comprising a carbon nanotube, a superconducting substrate in quantum proximity to the nanotube and being in a superconducting state having a pairing correlation matrix with a substantial spin-triplet component in a direction perpendicular to the nanotube, and a magnet arranged to provide a longitudinal magnetic field along a longitudinal axis of the nanotube. Further provided is a quantum computing device comprising at least three substrates made of a superconductor material and each in a superconducting state, and a non-superconducting structure made of a material in which the electrons' closed trajectories experience strong spin-orbit coupling interactions and being in quantum proximity to the substrates. The sum of the phase differences between the order parameters of all of the substrates is at least ?.
    Type: Application
    Filed: December 2, 2020
    Publication date: January 5, 2023
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., UNIVERSITY OF COPENHAGEN
    Inventors: Yuval OREG, Gal SHAVIT, Omri LESSER, Erez BERG, Adiel STERN, Karsten FLENSBERG
  • Patent number: 11497800
    Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: November 15, 2022
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
  • Patent number: 11498956
    Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: November 15, 2022
    Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, UNIVERSITY OF COPENHAGEN
    Inventors: Maria Rosaria Bassi, Riccardo Cortese, Anna Morena D'Alise, Antonella Folgori, Peter Johannes Holst, Alfredo Nicosia